Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Proteomics. 2008 Jun;5(3):445-55. doi: 10.1586/14789450.5.3.445.

High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS.

Author information

1
University Medical Center Rotterdam, Josephine Nefkens Institute, Laboratory of Genomics & Proteomics in Breast Cancer, Department of Medical Oncology, Dr. Molewaterplein 50, Be 430c, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. a.umar@erasmusmc.nl

Abstract

Discovery of better biomarkers for diagnosis, prognosis and therapy-response prediction is the most critical task of a scientific quest aimed at developing novel, tailormade therapies for patients with cancer. Consequently, a proteome-wide analysis, in addition to genomic studies, is an absolute requirement for a complete functional understanding of tumor biology. Ultra-sensitive, high-performance Fourier-transform ion-cyclotron resonance (FTICR) mass spectrometry (MS) currently holds an important role in fulfilling the demands of biomarker discovery. In this review, we describe the applicability of FTICR-MS for breast cancer proteomics, particularly for the analysis of complex protein mixtures obtained from a limited number of cells typically available from clinical specimens.

PMID:
18532912
DOI:
10.1586/14789450.5.3.445
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center